Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | Topotecan | Topo I | Chemotherapy | 0.0049855 | -0.4488 | 1.0175 | 0.4717 | 1.1814 | 0.0076404 | 0.9429 |
MDA-MB-453 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0034639 | -0.6347 | 1.0079 | 0.2403 | 0.8199 | 0.0064512 | 0.90769 |
MDA-MB-468 | Taxol | Chemo | Chemotherapy | 0.001354 | -0.5218 | 1.0076 | 0.5243 | 1.2795 | 0.0023644 | 0.95471 |
HCC1419 | Neratinib | EGFR/HER2 | RTK | 0.0011485 | -0.5015 | 0.9927 | 0.1818 | 0.5367 | 0.0038194 | 0.97246 |
HCC1419 | Topotecan | Topo I | Chemotherapy | 0.0071886 | -0.7857 | 0.9904 | 0.1711 | 0.4002 | 0.11192 | 0.94532 |
BT-20 | Taxol | Chemo | Chemotherapy | 0.0020158 | -0.5760 | 0.9854 | 0.4456 | 2.0677 | 0.0028795 | 0.99355 |
MDA-MB-157 | AZD7762 | CHK1/2 | Cell cycle | 0.015418 | -0.7858 | 0.9840 | 0.3122 | 0.8223 | 0.045445 | 0.98837 |
MDA-MB-361 | Luminespib | HSP90 | Misc | 0.0071417 | -0.8855 | 0.9781 | 0.3455 | 4.9987 | 0.0087421 | 0.9995 |
HCC70 | Taxol | Chemo | Chemotherapy | 0.0013411 | -0.5065 | 0.9773 | 0.3742 | 1.1642 | 0.0024269 | 0.99734 |
MDA-MB-361 | Taxol | Chemo | Chemotherapy | 0.0031082 | -0.6090 | 0.9738 | 0.2561 | 2.5508 | 0.0042111 | 0.9201 |
SK-BR-3 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0026508 | -0.5064 | 0.9712 | 0.2693 | 1.0983 | 0.0044617 | 0.98817 |
PDX1328 | Volasertib | PLK | Cell cycle | 0.0025124 | -0.5731 | 0.9694 | 0.2182 | 2.8453 | 0.0032751 | 0.99856 |
PDXHCI002 | Doxorubicin | Chemo | Chemotherapy | 0.0040539 | -0.6545 | 0.9685 | 0.2951 | 0.9297 | 0.0087544 | 0.98094 |
MDA-MB-157 | Doxorubicin | Chemo | Chemotherapy | 0.0032329 | -0.7766 | 0.9661 | 0.1885 | 0.9535 | 0.006701 | 0.93404 |
T47D | Topotecan | Topo I | Chemotherapy | 0.0052275 | -0.1971 | 0.9594 | 0.1261 | 1.3094 | 0.0068541 | 0.99083 |
Hs 578T | Taxol | Chemo | Chemotherapy | 0.0010154 | -0.3752 | 0.9535 | 0.4788 | 1.2811 | 0.0015458 | 0.95438 |
CAMA-1 | Taxol | Chemo | Chemotherapy | 0.0022699 | -0.4944 | 0.9525 | 0.3547 | 2.4920 | 0.0029769 | 0.99478 |
HCC1954 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0070107 | -0.3632 | 0.9490 | 0.3748 | 1.0954 | 0.010784 | 0.99379 |
MDA-MB-157 | Taxol | Chemo | Chemotherapy | 0.002046 | -0.6700 | 0.9482 | 0.3487 | 1.9966 | 0.0029397 | 0.97064 |
MDA-MB-134-VI | Luminespib | HSP90 | Misc | 0.0047553 | -0.7660 | 0.9424 | 0.2076 | 3.5318 | 0.006139 | 0.99851 |
SK-BR-3 | Doxorubicin | Chemo | Chemotherapy | 0.0067336 | -0.6156 | 0.9421 | 0.3142 | 1.5278 | 0.010801 | 0.99572 |
SUM149PT | Topotecan | Topo I | Chemotherapy | 0.0056894 | -0.4596 | 0.9408 | 0.4257 | 1.0455 | 0.0084398 | 0.94 |
MDA-MB-468 | Volasertib | PLK | Cell cycle | 0.002104 | -0.4485 | 0.9279 | 0.3934 | 2.9173 | 0.0026072 | 0.99938 |
MDA-MB-453 | Topotecan | Topo I | Chemotherapy | 0.0066897 | -0.5289 | 0.9258 | 0.1604 | 1.0131 | 0.010358 | 0.92364 |
HCC1500 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.0034818 | -0.1594 | 0.9249 | 0.0829 | 0.7537 | 0.0052374 | 0.99634 |